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Abstract
Aims/hypothesis The activation of NADPH oxidase has been
implicated in NEFA-induced beta cell dysfunction. However,
the causal role of this activation in vivo remains unclear.
Here, using rodents, we investigated whether pharmaco-
logical or genetic inhibition of NADPH oxidase could
prevent NEFA-induced beta cell dysfunction in vivo.
Methods Normal rats were infused for 48 h with saline or
oleate with or without the NADPH oxidase inhibitor apocy-
nin. In addition, NADPH oxidase subunit p47phox-null mice
and wild-type littermate controls were infused with saline or
oleate for 48 h. This was followed by measurement of
NADPH oxidase activity, reactive oxygen species (ROS)
and superoxide imaging and assessment of beta cell function
in isolated islets and hyperglycaemic clamps.
Results Oleate infusion in rats increased NADPH oxidase
activity, consistent with increased total but not mitochondrial
superoxide in islets and impaired beta cell function in isolated
islets and during hyperglycaemic clamps. Co-infusion of
apocynin with oleate normalised NADPH oxidase activity
and total superoxide levels and prevented beta cell dysfunc-
tion. Similarly, 48 h NEFA elevation in wild-type mice in-
creased total but not mitochondrial superoxide and impaired
beta cell function in isolated islets. p47phox-null mice
were protected against these effects when subjected to
48 h oleate infusion. Finally, oleate increased the levels
of total ROS, in both models, whereas inhibition of
NADPH oxidase prevented this increase, suggesting that
NADPH oxidase is the main source of ROS in this
model.
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Conclusions/interpretation These data show that NADPH-
oxidase-derived cytosolic superoxide is increased in islets
upon oleate infusion in vivo; and whole-body NADPH-
oxidase inhibition decreases superoxide in concert with resto-
ration of islet function.
Keywords Beta cell dysfunction . In vivo . Lipotoxicity .
NADPH oxidase . Oleate . Oxidative stress
Abbreviations
Ginf Glucose infusion rate
GSH/GSSG Reduced-to-oxidised glutathione ratio
GSIS Glucose-stimulated insulin secretion
H2DCF-DA Dihydro-dichlorofluorescein diacetate
HEt Hydroethidine
IKKβ Inhibitor of (nuclear factor) kappa
B kinase beta
JNK c-Jun-N-terminal kinase
KRBH Krebs–Ringer buffer containing
10 mmol/l HEPES
MDA Malonedialdehyde
M/I Glucose metabolism (M) divided by
plasma insulin (I)
MS MitoSOX
NFκB Nuclear factor kappa B
PKC Protein kinase C
RLU Relative luminescence units
ROS Reactive oxygen species
TBARS Thiobarbituric acid reacting substances
WT Wild-type
Introduction
Chronic exposure of pancreatic beta cells to NEFA impairs
beta cell function [1]. Although not all studies are concordant
[2], a growing body of evidence implicates oxidative stress as
a mechanism of NEFA-induced beta cell dysfunction [3–7].
Pancreatic beta cells have low antioxidant defences [8] and are
thus susceptible to decrease in function induced by reactive
oxygen species (ROS) [9]. We have previously demonstrated
that: (1) prolonged elevation of plasma NEFA in rats impairs
glucose-stimulated insulin secretion (GSIS) in vivo during
hyperglycaemic clamps and ex vivo in freshly isolated islets
and (2) treatment with antioxidants (N-acetylcysteine or tau-
rine or tempol), which decreases islet ROS measured with
dihydro-dichlorofluorescein diacetate (H2DCF-DA), prevents
the impairing effects of NEFA on beta cell function [10].
Zhang et al confirmed our findings in rats [10] in a different
model of prolonged NEFA elevation [11]. Our group has also
shown that the antioxidant taurine alleviated NEFA-induced
impairment in beta cell function in humans [12].
The type and cellular localisation of ROS involved in
NEFA-induced beta cell dysfunction are still unclear.
Although the mitochondrial electron transport chain was
traditionally regarded as the main source of ROS generation,
a growing body of evidence now suggests that NADPH
oxidase is also a source of ROS production in beta cells.
In fact, beta cells express NADPH oxidase (NOX1, NOX2
and NOX4 isoforms) [13, 14] which generates superoxide in
the cytosol/plasma membrane and components of this en-
zyme are elevated in islets of animal models of type 2
diabetes [15]. NOX1 and NOX2 are multi-subunit enzymes,
comprising cytosolic (p40phox, p47phox and p67phox and the
small protein rho rac) and membrane-bound (gp91phox and
p22phox) subunits. Upon activation (e.g. by protein kinase C
[PKC]), the cytosolic subunits migrate to the membrane, and
the complex assembles its components, leading to production
of superoxide radical [16]. Therefore, we hypothesised that
NEFA activate NADPH oxidase and that this enzyme is a
possible site of ROS generation in NEFA-induced beta cell
dysfunction.
To investigate the role of NADPH oxidase in fat-induced
beta cell dysfunction, the beta cell function was evaluated ex
vivo in isolated islets and in vivo during hyperglycaemic
clamps after prolonged elevation of plasma NEFA with or
without NADPH oxidase inhibition. We used two models of
NADPH oxidase inhibition: a pharmacological model
(apocynin treatment) and a genetic model (p47phox-knockout
mouse). Oleate is the most prevalent circulating fatty acid and
was used instead of the standard infusion of Intralipid and
heparin, because we have previously shown that the pro-
longed infusion of oleate impairs GSIS to a greater degree
than Intralipid and heparin [17].
Here we show that pharmacological or genetic inhibition
of NADPH oxidase prevents the increase in superoxide in
islets of oleate-treated rodents. In addition, this inhibition
prevents the impairing effect of oleate on beta cell function
assessed both ex vivo and in vivo. Therefore, NADPH
oxidase-derived superoxide plays a causal role in NEFA-
induced beta cell dysfunction in vivo, and is thus a potential
target for prevention of beta cell dysfunction in type 2
diabetes.
Methods
Animals All procedures were in accordance with the
Canadian Council of Animal Care Standards and were ap-
proved by the Animal Care Committee of the University of
Toronto. Female Wistar rats (250–300 g; Charles River,
Senneville, QC, Canada) and male mice (25–30 g) with
knockout of the p47phox subunit of NADPH oxidase, as
previously described [18] or their littermate wild-type con-
trols (WT) were used for experiments. Animals were housed
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in the University of Toronto’s Department of Comparative
Medicine. They were exposed to a 12 h light/dark cycle and
were fed rodent chow (Teklad Global 2018, Madison, WI,
USA).
Surgery and intravenous infusion All surgical procedures
were performed under general anaesthesia. The left jugular
vein and the right carotid artery of the rats were cannulated
as previously described [10]. After 3 days of recovery from
surgery, rats were randomised and infused for 48 h with
either: (1) NaCl (saline, 154 mmol/l) as control; (2) oleate
(OLE, 1.3 μmol/min; Sigma, St Louis, MO, USA), prepared
as described previously [10, 17], to elevate plasma NEFA by
1.5- to twofold; (3) oleate and apocynin (Calbiochem, La
Jolla, CA, USA); or (4) apocynin alone. Apocynin dissolved
in saline at pH 7.4 was given at a dose of 0.5 μmolkg−1min−1
[19].
In mice, an indwelling catheter was inserted into the right
internal jugular vein for infusion. After a minimum 3–4 day
period of post-surgery recovery, knockout and WT mice
were infused for 48 h with either saline or oleate to
elevate plasma NEFA by 1.5- to twofold. Oleate was
prepared as for rats and administered to mice at a dose of
0.4 μmol/min.
Pancreatic islet isolation After the 48 h infusion, islets were
isolated from the overnight-fasted rats using the
Ficoll/Histopaque method, as described previously [10].
Pancreatic islets of mice were isolated after a 5 h fast,
following 48 h infusion, as previously described [20].
NADPH oxidase activity assay The chemiluminescence
lucigenin assay was carried out using a single-tube lumin-
ometer (Berthold FB12; Berthold Technologies, Bad
Wildbad, Germany) modified to maintain the sample tem-
perature at 37°C [18]. Islets of rats were isolated as above.
Following 1 h of pre-incubation at 37°C in Krebs–Ringer
buffer with 10 mmol/l HEPES (KRBH) containing
2.8 mmol/l glucose, islets were washed in PBS and sus-
pended in 1 ml PBS. Lucigenin (5 μmol/l) and NADPH
(100 μmol/l) were added to the samples and light emission
was recorded every 2 min over a 15 min period. The results
were normalised per 1 mg protein. Islet protein was mea-
sured using the Bradford assay.
Islet NADPH/NADP+ measurement Islet NADPH and
NADP+ levels were measured from 200 islets of rats using
an NADPH/NADP+ quantification kit (Sigma). The levels
were normalised by mg of protein.
ROS measurement Islet ROS were measured using H2DCF-
DA (Sigma) [21], which detects most ROS, including hy-
drogen peroxide, lipid peroxides, peroxyl radical and
peroxynitrite anion [22]. However, H2DCF-DA does not
directly detect superoxide [23]. Total superoxide was mea-
sured by hydroethidine (HEt; Invitrogen, Burlington, ON,
Canada), and mitochondrial superoxide was measured by
MitoSOX (MS; Invitrogen) as described previously [21].
Thiobarbituric acid reacting substances (TBARS)
assay Lipid peroxidation in islets of rats was measured
indirectly by assay of the secondary product malondialde-
hyde (MDA) using the TBARS assay kit (Cayman Chemical
Company, Ann Arbor, MI, USA). The levels of MDA were
expressed as μmol/mg of islet protein.
Ex vivo evaluation of GSIS Isolated islets of rats and mice
were pre-incubated for 1 h at 37°C in KRBH supplemented
with 2.8 mmol/l glucose. Thereafter, five rat islets of ap-
proximately the same size were incubated in triplicate at 2.8,
6.5, 13 and 22 mmol/l glucose for 2 h at 37°C. Similarly, ten
mouse islets of approximately the same size were incubated
in duplicate at 6.5 and 22 mmol/l glucose for 2 h at 37°C.
Insulin concentration in the medium was analysed using a
radioimmunoassay kit specific for rat/mouse insulin (Linco,
St Charles, MO, USA). The islets used for secretion were
then subjected to acid ethanol extraction [21] for measure-
ment of insulin content.
In vivo evaluation of GSIS GSIS in vivo was determined by
measuring plasma insulin and C-peptide levels in rats during
two-step hyperglycaemic clamps. An infusion of 37.5%
glucose was started at time t=0 min. Plasma glucose was
maintained at 13 mmol/l by adjusting the rate of the glucose
infusion according to frequent (every 5–10 min) glucose
determinations. At 120 min, the glucose infusion was raised
to achieve and maintain plasma glucose levels of 22 mmol/l
until the end of the experiment (t=240 min). During the
clamp, blood samples were frequently drawn to measure
plasma NEFA, insulin and C-peptide levels.
Plasma assays Plasma NEFAwere measured with an enzy-
matic colorimetric kit (Wako Industries, Neuss, Germany).
Radioimmunoassay kits specific for rat/mouse insulin and
C-peptide (Linco) were used to determine plasma concen-
trations (interassay CV <10%). Plasma TBARS assay was
carried out as described above. The results are expressed in
nmol/l. The ratio of reduced glutathione to oxidised gluta-
thione (GSH/GSSG) in plasma was measured using the
GSH/GSSG EnzyChrom kit (BioAssays Systems,
Hayward, CA, USA).
Statistical analysis Data are means ± SEM. One-way non-
parametric ANOVA for repeated measurements followed by
Tukey’s t test was used to compare treatments. Calculations
were performed using SAS (Cary, NC, USA).
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Results
Plasma determinations in rats During the 48 h infusions, as
expected, the oleate-treated rats had higher plasma levels of
NEFA than the rats treated with saline or apocynin alone
(Table 1). The infusion of oleate and/or apocynin did not
affect plasma glucose or insulin (data not shown). Oleate
decreased the plasma GSH/GSSG and tended to increase the
plasma levels of MDA (a lipid peroxidation product)
(Table 2). The effects of oleate were prevented by the co-
infusion of apocynin.
Beta cell function ex vivo and determinations in rat
islets Forty-eight-hour oleate infusion increased the activity
of NADPH oxidase (p<0.05 vs SAL; Fig. 1a). This increase
was prevented by the co-infusion of apocynin. Oleate also
tended to increase the islet NADPH/NADP+ ratio (Fig. 1b).
As expected, this tendency was accentuated by apocynin.
Oleate elevated total islet superoxide (p<0.01 vs SAL;
Fig. 1c) but not mitochondrial superoxide (Fig. 1d). The
increase in total superoxide was reduced by apocynin (p<0.01
oleate vs oleate + apocynin; NS oleate + apocynin vs saline;
Fig. 1c). In addition, oleate elevated total ROS (p<0.01 vs
saline; Fig. 1e); this elevation was attenuated by apocynin
(p<0.05 oleate vs oleate + apocynin; NS saline vs oleate +
apocynin). Islets of rats treated with oleate showed an increase
in MDA (p<0.05 oleate vs saline; Fig. 1f), which was com-
pletely prevented by apocynin (p<0.01 oleate vs oleate +
apocynin).
After the 48 h infusions, we evaluated GSIS ex vivo in
freshly isolated islets. At 2.8 and 6.5 mmol/l of glucose,
insulin secretion did not differ among groups. The insulin
secretory response of islets isolated from oleate-infused rats
was markedly decreased compared with the response of
islets from rats infused with saline at both 13 (p<0.05 vs
saline) and 22 mmol/l (p<0.05 vs saline) glucose (Fig. 2a).
Apocynin prevented the oleate-induced decrease in insulin
secretion at both of these glucose concentrations. Likewise,
the islet insulin content was significantly decreased by ole-
ate (p<0.01 vs saline), but not in the presence of apocynin
(Fig. 2b).
Rat beta cell function in vivo As shown in Fig. 3a, basal
plasma NEFA levels before the hyperglycaemic clamps
were higher in oleate-treated rats than in control rats or rats
treated with apocynin alone (p<0.05). NEFA levels declined
during the clamp because of hyperglycaemia and hyperin-
sulinaemia. However, NEFA remained highest in oleate-
treated rats.
Basal plasma glucose was similar in all groups (Fig. 3b).
During the first step of the clamp, glucose levels rose to 13
mmol/l and during the second step, to 22 mmol/l, with no
differences among groups (Fig. 3b). The glucose infusion
rate (Ginf) required to maintain the target glucose level was
lower in the oleate-treated group than in the saline-treated
group, consistent with decreased insulin secretion, de-
creased insulin sensitivity, or both (p<0.01 oleate vs saline;
Fig. 3c). Apocynin, in combination with oleate, prevented
the lowering of Ginf by oleate (p<0.01 oleate vs oleate +
apocynin; Fig. 3c). Apocynin alone had no effect on Ginf.
Basal plasma insulin and C-peptide levels were similar in
all groups of rats. As expected, plasma insulin rose in response
to increasing glucose levels (Fig. 3d). Plasma C-peptide also
rose, indicating that the rise in insulin was due to increased
secretion (Fig. 3e). Plasma insulin and C-peptide were lower
in oleate-treated rats than in those treated with saline. In the
oleate + apocynin group plasma insulin and C-peptide were
similar to control levels (Fig. 3d and e). Apocynin alone had
no effect on insulin or C-peptide levels.
Ginf and insulin levels were proportionally decreased in
the oleate vs saline group; the sensitivity index (glucose
metabolism divided by plasma insulin [M/I]=Ginf/insulin
Table 1 Plasma NEFA levels before and after infusion in rats
Treatment n Time (h) NEFA (μmol/l) p value (vs SAL)
SAL 15 0 957±77 –
48 829±61 –
OLE 15 0 784±230 –
48 1,505±250 <0.05
OLE + APO 12 0 741±69 –
48 1,441±159 <0.01
APO 15 0 871±122 –
48 881±132 NS
Data are means ± SEM
Rats were treated for 48 h with: saline (SAL); oleate (OLE, 1.3 μmol/min),
to elevate plasma NEFA 1.5- to twofold; oleate + apocynin (OLE + APO,
1.3 μmol/min+0.5 μmolkg−1 min−1 , respectively) or apocynin (APO,
0.5 μmolkg−1 min−1 )






MDA (nmol/l) p value
(vs SAL)
SAL 6 52.1±3.6 – 0.0156±0.0012 –
OLE 6 14.8±1.4 <0.01 0.0213±0.0037 NSa
OLE + APO 6 53.0±5.4 NS 0.0126±0.0001 NS
APO 5 57.3±4.9 NS 0.0166±0.0002 NS
Data are means ± SEM
Rats were treated for 48 h with: saline (SAL); oleate (OLE, 1.3 μmol/min),
to elevate plasma NEFA 1.5- to twofold; oleate + apocynin (OLE + APO,
1.3 μmol/min+0.5 μmolkg−1 min−1 , respectively) or apocynin (APO,
0.5 μmolkg−1 min−1 )
a p<0.01 vs OLE + APO
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[24]) was not significantly different during either the first
step (0.42±0.027 μmolkg−1min−1 [pmol/l]−1 for saline and
0.43±0.016 μmolkg−1min−1 [pmol/l]−1 for oleate, NS) or
the second step (0.31±0.027 μmolkg−1min−1 [pmol/l]−1 for
saline and 0.34±0.01 μmolkg−1min−1 [pmol/l]−1 for oleate,
NS) of the clamp. Apocynin, either alone or in combination
with oleate, had no effect on M/I.
Studies in mice During the 48 h infusions, as expected, the
mice treated with oleate had higher plasma NEFA levels
than the mice treated with saline (Table 3). The infusion of
saline or oleate did not affect plasma glucose or insulin (data
not shown).
Forty-eight hours of oleate infusion elevated total islet
superoxide (p<0.01; Fig. 4a) but not mitochondrial super-
oxide (Fig. 4b) in WT mice. The increase in total superoxide
did not occur in islets of oleate-infused p47phox-knockout
mice. Forty-eight hours of oleate infusion elevated total
ROS in the islets of WT mice (p<0.01 vs WT-SAL;
Fig. 4c). There was no significant increase in total ROS in
the islets of p47phox-knockout mice infused with oleate. The
evaluation of GSIS ex vivo in freshly isolated mouse islets
(Fig. 5a) showed that at 6.5 mmol/l of glucose, there was no
significant difference among the different groups. However,
at 22 mmol/l glucose, 48 h oleate infusion in WT mice
impaired GSIS compared with saline infusions (p<0.01).
In contrast, p47phox-knockout mice subjected to 48 h elevation
of NEFA had no significant impairment in GSIS (p<0.01WT
treated with oleate vs knockout treated with oleate). Likewise,
the islet insulin content was significantly decreased in WT
mice infused with oleate as compared with saline (p<0.01 vs
SAL; Fig. 5b). p47phox-knockout mice were protected from
the oleate-induced decrease in islet insulin content.
Discussion
We herein investigated whether NADPH oxidase is a source
of ROS production in beta cells and whether NADPH oxi-
dase activation is causally linked to oleate-induced beta cell
dysfunction in vivo. As demonstrated previously by our
group [10, 17], 48 h oleate infusion impaired beta cell
function ex vivo in isolated islets and in vivo during hyper-
glycaemic clamps in association with an increase in markers
of oxidative stress. Although a transient increase in ROS
generation is required for GSIS in beta cells [25–28], chron-
ic oxidative stress leads to beta cell dysfunction [10, 21,
29–32]. In the present study, both genetic and pharmacolog-
ical inhibition of NADPH oxidase protected against the
impairing effects of oleate. Beta cells express NADPH ox-
idase [13] and components of this enzyme are elevated in
islets of animal models of type 2 diabetes [15]. In fact, the
inhibition of NADPH oxidase in islets of db/db mice par-
tially restored islet insulin content [15], suggesting that this



















































































































































Fig. 1 The NADPH oxidase inhibitor apocynin normalises NADPH
oxidase activity, total superoxide, total ROS and MDA levels increased
by oleate in rat islets. Rats were treated for 48 h with saline (SAL,
5 μl/min); oleate, to elevate plasma NEFA 1.5- to twofold (OLE,
1.3 μmol/min); oleate + apocynin (OLE + APO, 1.3 μmol/min+
0.5 μmolkg−1min−1, respectively) or apocynin (APO, 0.5 μmolkg−1
min−1). (a) NADPH oxidase activity in freshly isolated islets of the rats
treated as above. Data are means ± SEM (SAL, n=7; OLE, n=9; OLE +
APO, n=6; APO, n=6). (b) NADPH/NADP+ in freshly isolated islets of
the rats treated as above. Data are means ± SEM (n=6 per group). Total
(c) and mitochondrial (d) superoxide levels (n=6 rats per group) and total
ROS (e) levels (n=4 rats per group) in freshly isolated islets of rats treated
as above. Data are expressed as mean % of SAL ± SEM. The represen-
tative fluorescent images of islets stained with hydroethidine, MitoSOX
and H2DCF-DA are also shown. (f) MDA levels in freshly isolated islets
of rats treated as described above. Data are means ± SEM (SAL, n=7;
OLE, n=8; OLE + APO, n=9; APO, n=9); *p<0.05 OLE vs
SAL, **p<0.01 OLE vs SAL, †p<0.05 OLE vs OLE + APO and APO,
††p<0.01 OLE vs OLE + APO and APO, ‡‡p<0.01 OLE vs all
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Several in vitro studies have reported the causal effect of
the NEFA activation of NADPH oxidase in inducing beta
cell dysfunction [33–35]. One in vivo study investigated the













































Fig. 2 Apocynin prevents oleate-induced beta cell dysfunction ex vivo
in islets isolated from rats. (a) Insulin secretory response to glucose and
(b) islet insulin content in freshly isolated islets of rats treated as
described in the Fig. 1 legend. Data are means ± SEM (saline [SAL],
n=7; oleate [OLE], n=7; OLE + apocynin [APO], n=7; APO, n=8);
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Fig. 3 Apocynin prevents the decrease in beta cell function induced
by oleate in vivo during two-step hyperglycaemic clamp in rats. Rats
were treated as described in the Fig. 1 legend. Plasma levels of NEFA
(a), glucose (b), insulin (d) and C-peptide (e) and glucose infusion rate
(Ginf) (c) were measured during the two-step hyperglycaemic clamp.
Data are means ± SEM (saline [SAL], n=8; oleate [OLE], n=8;
OLE + apocynin [APO], n=5; APO, n=7); **p<0.01 OLE vs
SAL, ***p<0.001 OLE vs SAL, †p<0.05 OLE vs OLE + APO,
‡‡p<0.01 OLE vs all. White circles, SAL; black circles, OLE;
black squares, OLE + APO; white squares, APO
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rats and found decreased subunit content and ROS concen-
trations in islets, with elevated GSIS in order to overcome
the high-fat-diet-induced insulin resistance [36]. The find-
ings of the latter study conflict with those of other studies
showing that high-fat diet induces oxidative stress in islets
of rats [29, 30]. Other in vivo studies using apocynin dem-
onstrate a role for NADPH oxidase in high-fat-diet-induced
insulin resistance [37, 38]. However, this is the first in vivo
study that has investigated the causal effect ofNADPH oxidase
in fat-induced beta cell dysfunction. We have shown that 48 h
infusion of oleate activated NADPH oxidase and increased
total, but not mitochondrial, superoxide in islets. A similar
finding was reported in myocytes by Yuzefovych et al [39].
Pharmacological or genetic inhibition of NADPH oxidase
prevented the NEFA-induced increase in cytosolic superoxide
in islets and decrease in secretory function of beta cells.
NADPH is a substrate for NADPH oxidase. Oleate in-
creased the NADPH/NADP+ ratio in accordance with the
findings of previous studies [40, 41], despite increasing
NADPH oxidase activity. The effect of oleate on
NADPH/NADP+ ratio is likely a result of increased provision
of acetyl-CoA to the Krebs cycle (increased production) [40]
in association with some impairment in electron transport
system flux (increased redox ratio) [42]. When NADPH oxi-
dase activity is inhibited, the NADPH already generated from
fat accumulates. NADPH is a substrate for thioredoxin and
glutaredoxin [43], which are antioxidants involved in mediat-
ing insulin secretion and can also increase insulin secretion via
inhibition of Kv channels [44]. Therefore, we cannot rule out
the possibility that the increase in NADPH contributes to the
beneficial effects of inhibition of GSIS by NADPH oxidase,
via reduced oxidative stress and/or independent effects of
NADPH.
Here, we showed that NADPH oxidase is the source of
superoxide production in a model of 48 h oleate-induced beta
cell dysfunction, as oleate did not elevate the levels of mito-
chondrial superoxide. The latter finding is consistent with our
previous result in MIN6 cells where superoxide dismutase
(Sod2) mRNA was unchanged after 48 h exposure to oleate
[10]; however, we cannot exclude the possibility that mito-
chondrial superoxide is increased at other time points.
Superoxides are short-lived; thus, their impairing effects
could be due to their conversion into other types of ROS that
are known to impair beta cell function [9]. To assess this
conversion, islets were isolated and imaged with H2DCF-
DA, which detects total ROS except superoxide [23]. We
Table 3 Plasma NEFA levels before and after 48 h infusion in mice
Mouse and
treatment
n Time (h) NEFA (μmol/l) p value
(vs SAL)
WT-SAL 8 0 415±59 –
48 372±50 –
WT-OLE 7 0 605±49 –
48 1,212±110 <0.001
KO-OLE 7 0 513±72 –
48 1,269±340 <0.01
KO-SAL 6 0 504±67 –
48 350±110 NS
Data are means ± SEM
p47phox -knockout mice (KO) and their WT littermate controls were
treated for 48 h with saline (SAL) or oleate (OLE, 0.4 μmol/min), to
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Fig. 4 The genetic deletion of p47phox in mice normalises total super-
oxide and total ROS levels increased by oleate in islets. p47phox-null
mice (KO) and their WT littermate controls were treated for 48 h with
saline (SAL, 0.5 μl/min) or oleate (OLE, 0.4 μmol/min) to elevate
plasma NEFA 1.5- to twofold. Total (a) and mitochondrial (b) super-
oxide levels (WT-saline [SAL], n=7; WT-oleate [OLE], n=6; KO-
OLE, n=6; KO-SAL, n=4) and total ROS (c) levels (WT-SAL, n=6;
WT-OLE, n=6; KO-OLE, n=7; KO-SAL, n=3) in freshly isolated
islets of the mice treated as above. Data are expressed as mean % of
SAL ± SEM; ‡‡p<0.01 WT-OLE vs all. The representative fluorescent
images of islets imaged with HEt, MitoSOX and H2DCF-DA are also
shown
1084 Diabetologia (2013) 56:1078–1087
found that pharmacological or genetic inhibition of NADPH
oxidase prevents the increase in ROS caused by oleate, im-
plying that extramitochondrial superoxide is converted to
other ROS.Moreover, in our pharmacological inhibition mod-
el, co-infusion of apocynin normalised the levels of MDA (an
indication of lipid peroxidation), suggesting that lipid perox-
ides are one of the ROS generated from extramitochondrial
superoxide. These observations are in accordance with previ-
ous studies wherein NADPH oxidase inhibition also reduced
total ROS [45] and lipid peroxides [4].
During the in vivo hyperglycaemic clamp studies, oleate-
treated rats showed lower insulin and C-peptide responses to
glucose compared with saline-treated rats. These results indi-
cate reduced insulin secretion, an effect consistent with that
observed ex vivo in isolated islets. Insulin secretion during
hyperglycaemic clamps should be interpreted in the context of
insulin sensitivity because in vivo normal beta cells compen-
sate for insulin resistance by increasing insulin secretion inde-
pendently of plasma glucose. Although NEFA induce insulin
resistance, this effect was not observed in our rat model,
consistent with our previous studies performed using the same
oleate infusion protocol in the same animal model [10, 17].
Insulin resistance could not be detected likely due to a number
of factors, including the moderate elevation of NEFA, their
monounsaturation, the female sex of the rats and the use of the
hyperglycaemic clamp rather than the gold-standard hyper-
insulinaemic–euglycaemic clamp. Since insulin sensitivity
was not changed, the beta cell did not need to secrete more
insulin to compensate for insulin resistance; therefore, our in
vivo GSIS results are similar to the results obtained ex vivo.
The reason for using a genetic mouse model of NADPH
oxidase inhibition is that all pharmacological inhibitors may
have nonspecific effects. It has been argued that apocynin
does not act as an NADPH oxidase inhibitor but as an antiox-
idant [46]. Several mouse models of NADPH oxidase subunit
knockout exist; however, special attention has been paid to the
p47phox subunit [3, 33, 35] when investigating beta cell func-
tion.We used amodel that targets the p47phox subunit because:
(1) the NADPH oxidase inhibitor used in rats, apocynin, acts
by inhibiting the translocation of the p47phox subunit to the
plasma membrane subunits [47], therefore, the use of this
knockout mouse model allows us to draw a parallel with our
studies in rats; and (2) activation of PKC by NEFA leads to
serine phosphorylation of the p47phox subunit, thus allowing it
to translocate to the membrane subunits and activate the
enzyme complex [48]. Indeed we have shown that NEFA
tends to increase the phosphorylation of p47phox at serine
328, which is a direct phosphorylation site by PKC (electronic
supplementary material [ESM] Fig. 1). Therefore, the p47phox
subunit is fundamental in the mechanism of fat-induced beta
cell dysfunction. Recently, some of us have shown that knock-
out of p47phox subunit also protects against diabetes in Akita
mice [18].
The contribution of the systemic effect of NADPH oxi-
dase inhibition towards beta cell function cannot be ruled
out in our model. Markers of circulating whole-body redox,
such as reduced-to-oxidised glutathione ratio (GSH/GSSG),
were decreased and the levels of the lipid peroxidation
product MDA tended to be increased by oleate in the plasma
of rats. Such changes were prevented by the co-infusion of
apocynin (Table 2). Hence, these results suggest that the
inhibition of systemic NADPH oxidase could contribute to
the preservation of islet function by elevating the systemic
redox ratio as well as by reducing systemic oxidative stress.
The precise mechanism by which NADPH oxidase-
derived ROS impair beta cell function is not completely
clear but several mechanisms have been proposed. First,
oxidative stress can inhibit glucose metabolism in the beta
cell [49]. Although cytosolic glycolysis may be affected,
extramitochondrial ROS can also induce mitochondrial dys-
function [4, 45]. Second, oxidative stress may affect insulin










































Fig. 5 The genetic deletion of p47phox in mice prevents oleate-induced
beta cell dysfunction ex vivo in isolated islets. (a) Insulin secretory
response to glucose and (b) islet insulin content in freshly isolated islets of
p47phox-null mice (KO) and their WT littermate controls treated as
described in the Fig. 4 legend. Data are means ± SEM (WT-saline
[SAL], n=8; WT-oleate [OLE], n=7; KO-OLE, n=7; KO-SAL, n=6);
**p<0.01 KO-OLE vs WT-SAL, ‡‡p<0.01 WT-OLE vs all
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content we found in both rats and mice infused with oleate,
in accordance with Nakayama et al [15]. In summary, our
study demonstrates that prolonged exposure to oleate, which
increases ROS in islets via NADPH oxidase, decreases
GSIS both ex vivo and in vivo, and that NADPH oxidase
inhibition prevents the impairing effects of oleate. These
findings are the first direct in vivo demonstration of a causal
role for NADPH oxidase in the NEFA-induced decrease in
beta cell function. Therefore, NADPH oxidase inhibition
may be considered among the therapeutic targets aimed at
ameliorating beta cell function in type 2 diabetes.
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